Fingerprint Dive into the research topics of 'In severe asthma, benralizumab reduced daily oral glucocorticoid dose and asthma exacerbations at 6 months'. Together they form a unique fingerprint.
- Sort by
- Weight
- Alphabetically
In severe asthma, benralizumab reduced daily oral glucocorticoid dose and asthma exacerbations at 6 months
Diego J. Maselli, Jay I Peters
Research output: Contribution to journal › Comment/debate › peer-review
1
Scopus
citations